Publication Name	World Journal of Gastroenterology
Manuscript ID	33459
Country	United States

Received	2017-02-09 08:54
Peer-Review Started	2017-02-09 16:07
To Make the First Decision	2017-04-21 08:28
Return for Revision	2017-04-24 16:22
Revised	2017-05-09 02:39
Second Decision	2017-06-12 05:55
Accepted by Journal Editor-in-Chief	2017-06-12 09:21
Accepted by Executive Editor-in-Chief	2017-06-19 09:08
Articles in Press	2017-06-19 09:08
Publication Fee Transferred	2017-07-26 03:34
Edit the Manuscript by Language Editor
Typeset the Manuscript	2017-09-04 03:10
Publish the Manuscript Online	2017-09-07 08:51

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access
Copyright	© The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Retrospective Cohort Study
Article Title	Real-world treatment patterns of gastrointestinal neuroendocrine tumors: A claims database analysis
Manuscript Source	Unsolicited Manuscript
All Author List	Al B Benson III, Michael S Broder, Beilei Cai, Eunice Chang, Maureen P Neary and Elya Papoyan
Funding Agency and Grant Number	Funding Agency Grant Number Novartis Pharmaceuticals, One Health Plaza, East Hanover NJ 07936-1080
Corresponding Author	Michael S Broder, MD, MHSc, Partnership for Health Analytic Research, LLC, 280 S. Beverly Drive, Suite 404, Beverly Hills, CA 90212, United States. mbroder@pharllc.com
Key Words	Gastrointestinal neuroendocrine tumors; Treatment patterns; Insurance claims; Somatostatin analogue; Targeted therapy; Chemotherapy
Core Tip	In this retrospective study of real-world treatment patterns, somatostatin analogues were the most common initial pharmacologic treatment in patients with gastrointestinal neuroendocrine tumors, and most of the remaining patients began treatment with chemotherapy. However, despite the many treatment options, over half of the patients discontinued treatments after first line and only less than 10% of patients received any second-line pharmacotherapy. Given limitations of claims data to elucidate reasons for this lack of continued treatment, a study using more detailed clinical information such as medical charts or physician surveys is warranted.
Publish Date	2017-09-07 08:51
Citation	Benson III AB, Broder MS, Cai B, Chang E, Neary MP, Papoyan E. Real-world treatment patterns of gastrointestinal neuroendocrine tumors: A claims database analysis. World J Gastroenterol 2017; 23(33): 6128-6136
URL	http://www.wjgnet.com/1007-9327/full/v23/i33/6128.htm
DOI	http://dx.doi.org/10.3748/wjg.v23.i33.6128

Full Article (PDF)	WJG-23-6128.pdf
Full Article (Word)	WJG-23-6128.doc
Manuscript File	33459-Review.docx
Answering Reviewers	33459-Answering reviewers.pdf
Audio Core Tip	33459-Audio core tip.mp3
Conflict-of-Interest Disclosure Form	33459-Conflict-of-interest statement.pdf
Copyright License Agreement	33459-Copyright assignment.pdf
Signed Informed Consent Form(s) or Document(s)	33459_WJG Informed Consent GI NET Tx Patterns.pdf
Institutional Review Board Approval Form or Document	33459-Institutional review board statement.pdf
Peer-review Report	33459-Peer-review(s).pdf
Journal Editor-in-Chief Review Report	33459-Journal editor-in-chief review report.pdf
Scientific Misconduct Check	33459-Scientific misconduct check.pdf
Scientific Editor Work List	33459-Scientific editor work list.pdf